RxDoctor Payments DataLook up a doctor →

Amylynne Frankel, MD

Dermatology · Spartanburg, SCNPI 1437318607

Payments from drug & device makers

$1,334,414in general payments, 2019–2025

Across 2,118 payments — averaging $630.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$346K
  • Lilly USA, LLC$329K
  • Sun Pharmaceutical Industries Inc.$261K
  • Dermavant Sciences, Inc.$80K
  • Incyte Corporation$75K
  • Eli Lilly$71K
  • plus $172K from 23 others
$1,829in research payments, 2019–2025

Across 2 payments — averaging $914.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$2K

What the payments were for

  • Consulting fees$15,9452%
  • Speaking & faculty fees$783,42279%
  • Travel & lodging$144,12715%
  • Food & beverage$42,9934%
  • Education$8420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,334,414 in reported general payments places this provider in the 95th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,101,179
Medicare patients
1,724
Services billed
11,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab183$710,336
Skyrizi PenRisankizumab-Rzaa18$378,934
TremfyaGuselkumab13$180,075
Bimzelx AutoinjectorBimekizumab-Bkzx12$171,347
Taltz AutoinjectorIxekizumab19$133,238
Cosentyx Unoready PenSecukinumab15$123,340
AdbryTralokinumab-Ldrm26$92,719
Cosentyx Sensoready (2 Pens)Secukinumab12$89,148
RinvoqUpadacitinib12$78,569
Dupixent SyringeDupilumab16$61,119
OtezlaApremilast12$60,715
Tacrolimus110$18,336
Fluorouracil110$6,716
Clobetasol Propionate178$5,763
Ketoconazole289$5,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,646$180,07513 claims
LEO Pharma Inc.Adbry$1,730$92,71926 claims
AbbVieRinvoq$345,688$78,56912 claims
AmgenOtezla$1,268$60,71512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 dermatology providers in South Carolina.

Other dermatology in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →